T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)

RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2023 /PRNewswire/ — T3D Therapeutics, Inc. (“T3D”) a clinical stage drug development company engaged in the development of T3D-959, a new orally administered drug intended for the treatment of mild-to-moderate Alzheimer’s disease (AD), announced today it has been selected to present, as late breaking news, topline results from its Phase 2 PIONEER clinical trial of T3D-959 in mild-to-moderate severity AD patients at the 16th international conference on Clinical Trials in Alzheimer’s Disease (CTAD).

Read Full Press Release Here